David Grinblatt to Humans
This is a "connection" page, showing publications David Grinblatt has written about Humans.
Connection Strength
0.172
-
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research. Oncologist. 2023 08 03; 28(8):657-663.
Score: 0.031
-
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015 Apr; 56(4):887-95.
Score: 0.017
-
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
Score: 0.011
-
Review: coagulopathy and factor inhibitors. Clin Adv Hematol Oncol. 2008 Dec; 6(12):925-7.
Score: 0.011
-
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and Reporting. J Mol Diagn. 2023 08; 25(8):611-618.
Score: 0.008
-
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplant Cell Ther. 2023 07; 29(7):460.e1-460.e9.
Score: 0.008
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.007
-
Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. JCO Oncol Pract. 2021 03; 17(3):153-155.
Score: 0.006
-
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol. 2021 Jun; 43(3):426-432.
Score: 0.006
-
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020 04 14; 4(7):1407-1418.
Score: 0.006
-
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2.
Score: 0.005
-
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Oncologist. 2018 02; 23(2):159-170.
Score: 0.005
-
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017 03 16; 17(1):198.
Score: 0.005
-
Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903.
Score: 0.005
-
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 08 19; 16:652.
Score: 0.005
-
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer. 2013 Oct; 21(10):2853-60.
Score: 0.004
-
Response of pancreatic carcinoma to 5-fluorouracil and leucovorin. Am J Med. 1992 Jan; 92(1):107-9.
Score: 0.003
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.003
-
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1434-41.
Score: 0.003
-
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol. 2008 Feb; 140(3):313-9.
Score: 0.003
-
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant. 2006 Jul; 38(2):95-100.
Score: 0.002
-
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 Mar; 37(6):553-7.
Score: 0.002
-
Immunoglobulin for concurrent Guillain-Barré and immune thrombocytopenic purpura. Pediatr Neurol. 2006 Jan; 34(1):60-2.
Score: 0.002
-
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206.
Score: 0.002
-
Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40.
Score: 0.002
-
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant. 2001 Apr; 27(7):677-81.
Score: 0.002
-
Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Cytotherapy. 2000; 2(3):179-85.
Score: 0.002
-
Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. J Clin Apher. 1999; 14(1):31-4.
Score: 0.001
-
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. Cancer. 1998 Oct 15; 83(8):1540-5.
Score: 0.001
-
High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant. 1998 Jan; 21(2):127-32.
Score: 0.001
-
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant. 1995 Jun; 15(6):935-42.
Score: 0.001
-
Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck. Invest New Drugs. 1994; 12(1):45-7.
Score: 0.001